---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-030866"
form_type: "8-K"
ticker: "ARWR"
cik: "0000879407"
company_name: "ARROWHEAD PHARMACEUTICALS, INC."
filed_at: "2022-11-28T23:59:59+00:00"
generated_at: "2026-06-21T12:55:43.889118+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Arrowhead Pharma reports FY22 revenue up but net loss widens to $172.7M; $250M royalty sale

## Summary
- Revenue $243.2M for FY22 (Sep 30 yr-end), up 76% from $138.3M in FY21.
- Net loss $172.7M ($1.67 diluted loss per share) vs $140.8M ($1.36) prior year.
- Sold olpasiran royalty interest to Royalty Pharma for $250M cash plus up to $160M milestones.
- Phase 2 studies for ARO-APOC3 and ARO-ANG3 fully enrolled; new Phase 1/2a starts for ARO-MUC5AC, ARO-RAGE, ARO-MMP7.
- Cash and investments $482.3M at Sep 30, 2022, down from $613.4M at Sep 30, 2021.

## SEC filing metadata
- accession: 0001628280-22-030866
- form_type: 8-K
- ticker: ARWR
- cik: 0000879407
- company_name: ARROWHEAD PHARMACEUTICALS, INC.
- filed_at: 2022-11-28T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/879407/000162828022030866/0001628280-22-030866-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/879407/000162828022030866/arwr-20221128.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-030866
- JSON: https://secwatch.observer/filing/0001628280-22-030866.json
- Plain text: https://secwatch.observer/filing/0001628280-22-030866.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.